Injectable cartilage matrix hydrogel loaded with cartilage endplate stem cells engineered to release exosomes for non-invasive treatment of intervertebral disc degeneration

一种可注射的软骨基质水凝胶,负载有软骨终板干细胞,经基因工程改造可释放外泌体,用于非侵入性治疗椎间盘退变。

阅读:5
作者:Liwen Luo ,Junfeng Gong ,Zhouguang Wang ,Yao Liu ,Jiaming Cao ,Jinghao Qin ,Rui Zuo ,Hongyu Zhang ,Shuai Wang ,Ping Zhao ,Di Yang ,Mengjie Zhang ,Yanqiu Wang ,Junfeng Zhang ,Yue Zhou ,Changqing Li ,Bing Ni ,Zhiqiang Tian ,MingHan Liu

Abstract

Low back pain, mainly caused by intervertebral disc degeneration (IVDD), is a common health problem; however, current surgical treatments are less than satisfactory. Thus, it is essential to develop novel non-invasive surgical methods for IVDD treatment. Here, we describe a therapeutic strategy to inhibit IVDD by injecting hydrogels modified with the extracellular matrix of costal cartilage (ECM-Gels) that are loaded with cartilage endplate stem cells (CESCs). After loaded with CESCs overexpressing Sphk2 (Lenti-Sphk2-CESCs) and injected near the cartilage endplate (CEP) of rats in vivo, ECM-Gels produced Sphk2-engineered exosomes (Lenti-Sphk2-Exos). These exosomes penetrated the annulus fibrosus (AF) and transported Sphk2 into the nucleus pulposus cells (NPCs). Sphk2 activated the phosphatidylinositol 3-kinase (PI3K)/p-AKT pathway as well as the intracellular autophagy of NPCs, ultimately ameliorating IVDD. This study provides a novel and efficient non-invasive combinational strategy for IVDD treatment using injectable ECM-Gels loaded with CESCs that express Sphk2 with sustained release of functional exosomes. Keywords: Engineered exosomes; Extracellular matrix of costal cartilage; Hydrogels; Intervertebral disc degeneration; Sphingosine kinase 2.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。